Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Free Report) traded down 11.9% on Tuesday . The company traded as low as $0.36 and last traded at $0.3693. 5,714 shares traded hands during trading, a decline of 35% from the average session volume of 8,801 shares. The stock had previously closed at $0.4193.
Algernon Pharmaceuticals Price Performance
The business has a 50 day moving average price of $0.32 and a 200 day moving average price of $0.23.
Algernon Pharmaceuticals Company Profile
Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.
The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).
Further Reading
- Five stocks we like better than Algernon Pharmaceuticals
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
